SCHEMBL31376472

SCHEMBL31376472

CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(=N)N)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 12/20 0.51
NPY1R P25929 7/20 0.51
NPY2R P49146 5/20 0.51
NPY5R Q15761 5/20 0.51
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
FURIN P09958 3/20 0.40
NMT2 O60551 1/20 0.40
NMT1 P30419 1/20 0.40
SIRT6 Q8N6T7 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
DPP8 Q6V1X1 1/20 0.38
DPP9 Q86TI2 1/20 0.38
DPP7 Q9UHL4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29378646 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL30422560 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL30121066 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL8742594 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL8742615 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL30423395 1.00 NPY4R (0.51) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL29642059 0.96 NPY4R (0.48) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL10944182 0.95 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL10940273 0.95 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL10942024 0.95 NPY4R (0.47) NPY4RNPY1RNPY2RNPY5RGNAI3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007602-A1 Neutral Liposomes Containing Biologically Active Agents UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2026-01-08 US disclosed
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES ENTRADA THERAPEUTICS, INC. 2025-07-31 US disclosed
US-20250101063-A1 POLYPEPTIDE COMPOUND AND USE THEREOF IN TREATMENT OF ENTERITIS SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250243244-A1 CYCLIC CELL PENETRATING PEPTIDES SLC47A1, SLC47A2, VIP NPY4R 2162/4885NPY1R 1441/4885NPY2R 1575/4885
US-20260007602-A1 Neutral Liposomes Containing Biologically Active Agents NPC1L1, MCM7, LIPA NPY4R 1405/4885NPY1R 1569/4885NPY2R 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.